EKSO BIONICS HOLDING (OTCBB:EKSO) has received a “strong buy” rating from analysts. The bio-tech company is currently reviewed by three brokerages. EKSO operates in a very unique market, with very little to no competition. The company’s flagship product, an exoskeleton, is slowly becoming the product of choice for people suffering from paralysis. Anyone wanting to settle in long-term can surely expect a huge return. Some experts even suggest that the stock may report a climb of 1,600% within the next 5-years.
Analyst reports suggest that the company would have a price target of $2.83 for the next twelve months, with EPS at $0.04 for the current quarter. The company reported its last quarter EPS of $0.06, beating analyst estimates by $0.03. The Chief Investment strategist at Money Morning, Fitz Gerald, stated that he expects EKSO to hold a 25% share in the human augmentation market by 2020.
While there are other companies trying to make exoskeletons similar to that of EKSO, but none of them are as user friendly as EKSO’s. In his report, Mr. Gerald, stated that it takes very little time to get used to. One of the reasons can be how the suit adjusts to the needs of different users. However, medical applications are not the only ones that the bio-tech company is concentrating on. There are a number of military and industrial applications that EKSO is working towards as well.
EKSO had recently announced that it has obtained a third contract from the US Special Operations Command. As per the details, EKSO has been asked to work on the next phase of the “Tactical Assault Light Operator Suit”. The company’s projects with the US government and DARPA have resulted in three patents for the company. The TALOS is also being developed in phases and EKSO has been called in a third time, representing the quality of work the company is doing.
EKSO BIONICS HOLDING (OTCBB:EKSO) closed at $2, after gaining 3.63% on May 20. The company has 102.06 million shares being traded in the market, with a 52-week range of $0.75-$3.13.